Silence Therapeutics plc (SLNCF)
OTCMKTS
· Delayed Price · Currency is USD
1.470
0.00 (0.00%)
Feb 14, 2025, 4:00 PM EST
Silence Therapeutics Revenue
Silence Therapeutics had revenue of 1.14M GBP in the quarter ending September 30, 2024, a decrease of -59.19%. This brings the company's revenue in the last twelve months to 16.25M, down -42.07% year-over-year. In the year 2023, Silence Therapeutics had annual revenue of 25.38M with 44.99% growth.
Revenue (ttm)
16.25M GBP
Revenue Growth
-42.07%
P/S Ratio
n/a
Revenue / Employee
149.04K GBP
Employees
109
Market Cap
228.52M USD
Revenue Chart
* This company reports financials in GBP.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 25.38M | 7.87M | 44.99% |
Dec 31, 2022 | 17.50M | 5.09M | 40.97% |
Dec 31, 2021 | 12.42M | 6.94M | 126.59% |
Dec 31, 2020 | 5.48M | 5.24M | 2,145.49% |
Dec 31, 2019 | 244.00K | - | - |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Endo Inc. | 1.79B |
SS Innovations International | 16.04M |
Veradigm | 1.53B |
Elite Pharmaceuticals | 70.00M |
Glass House Brands | 188.29M |
Northwest Biotherapeutics | 1.60M |
BioStem Technologies | 210.49M |
SANUWAVE Health | 29.30M |
Silence Therapeutics News
- 4 days ago - Silence Therapeutics to Report Fourth Quarter and Full Year 2024 Results on February 27, 2025 - Business Wire
- 5 days ago - Lombard Odier Asset Management's Strategic Acquisition in Silence Therapeutics PLC - GuruFocus
- 6 days ago - Silence Therapeutics hit with new Sell at Goldman Sachs on resource constraints - Seeking Alpha
- 6 weeks ago - Silence Therapeutics: Simply No Match For Its Orally Dosed Rival (Downgrade) - Seeking Alpha
- 2 months ago - Top 3 Health Care Stocks That May Explode In Q4 - Benzinga
- 2 months ago - Top 3 Health Care Stocks That May Explode In Q4 - Benzinga
- 2 months ago - Silence Therapeutics Presents Promising Phase 1 Data in Polycythemia Vera Patients at the American Society of Hematology (ASH) Annual Meeting - Business Wire
- 2 months ago - Silence Therapeutics to Participate in Fireside Chat at Piper Sandler 36th Annual Healthcare Conference - Business Wire